Lauren Averett Byers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2768403/publications.pdf

Version: 2024-02-01

		38742	20358
126	15,137	50	116
papers	citations	h-index	g-index

134	134	134	22234
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	28.9	1,242
2	An Epithelialâ€“Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	7.0	848
3	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	12.8	780
4	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
5	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer, 2019, 19, 289-297.	28.4	692
6	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 2019, 9, 646-661.	9.4	555
7	Small cell lung cancer: Where do we go from here?. Cancer, 2015, 121, 664-672.	4.1	459
8	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	12.8	456
9	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811.	9.4	432
10	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	16.8	422
11	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncology, The, 2017, 18, 42-51.	10.7	412
12	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	7.0	388
13	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
14	Epithelialâ€“Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642.	7.0	353
15	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discovery, 2018, 8, 1156-1175.	9.4	323
16	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	9.4	321
17	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	1.6	276
18	PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clinical Cancer Research, 2019, 25, 3759-3771.	7.0	265

#	Article	IF	Citations
19	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology, 2014, 32, 644-652.	17.5	257
20	Giving AXL the axe: targeting AXL in human malignancy. British Journal of Cancer, 2017, 116, 415-423.	6.4	245
21	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
22	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature, 2017, 546, 168-172.	27.8	222
23	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nature Communications, 2020, 11, 4520.	12.8	218
24	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218
25	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	16.8	190
26	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. Clinical Cancer Research, 2015, 21, 2244-2255.	7.0	179
27	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer, 2018, 124, 807-815.	4.1	169
28	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Research, 2017, 77, 3870-3884.	0.9	163
29	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 2017, 8, 28575-28587.	1.8	157
30	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	1.1	156
31	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3638-3647.	1.6	140
32	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	12.8	122
33	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Molecular Cell, 2019, 76, 838-851.e5.	9.7	119
34	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
35	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 6852-6861.	7.0	105
36	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. Journal of Thoracic Oncology, 2020, 15, 248-257.	1.1	97

#	Article	IF	Citations
37	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Translational Lung Cancer Research, 2018, 7, 50-68.	2.8	96
38	Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. Journal of Thoracic Oncology, 2020, 15, 274-287.	1.1	95
39	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology, 2020, 15, 777-791.	1.1	94
40	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 6239-6253.	7.0	93
41	Integrative Analysis Identifies a Novel AXLâ€“PI3 Kinaseâ€“PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 2713-2722.	7.0	91
42	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. Journal of Thoracic Oncology, 2019, 14, 2152-2163.	1.1	80
43	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget, 2017, 8, 73419-73432.	1.8	74
44	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research, 2017, 15, 45-58.	3.4	73
45	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2014, 13, 2738-2750.	4.1	72
46	Dual Targeting of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Pathways: Rationale and Clinical Applications for Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2007, 8, S79-S85.	2.6	68
47	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discovery, 2021, 11, 2506-2523.	9.4	68
48	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0152584.	2.5	65
49	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clinical Cancer Research, 2016, 22, 4643-4650.	7.0	64
50	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
51	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 266-273.	1.1	58
52	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology, 2010, 5, 1894-1904.	1.1	57
53	Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiotherapy and Oncology, 2018, 126, 499-505.	0.6	56
54	Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Seminars in Oncology, 2016, 43, 476-483.	2.2	55

#	Article	IF	Citations
55	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019, 10, 3485.	12.8	54
56	Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecologic Oncology, 2016, 141, 588-591.	1.4	53
57	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. Journal of Thoracic Oncology, 2020, 15, 1919-1927.	1.1	53
58	The MEK5â€“ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. Cancer Research, 2020, 80, 1293-1303.	0.9	49
59	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	7.0	48
60	Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition. Cancer Cell, 2015, 28, 4-6.	16.8	46
61	Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer. Scientific Reports, 2014, 4, 4480.	3.3	44
62	Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer. Molecular Cancer Therapeutics, 2010, 9, 1755-1763.	4.1	43
63	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	12.4	42
64	Epithelialâ€“Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitorâ€“Mediated Apoptosis in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1674-1686.	7.0	41
65	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Communications, 2021, 12, 2606.	12.8	41
66	Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-NaÃ¯ve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clinical Cancer Research, 2021, 27, 3884-3895.	7.0	40
67	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
68	CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research, 2018, 78, 781-797.	0.9	37
69	NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells, 2020, 9, 2677.	4.1	37
70	Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers. Cancer Discovery, 2019, 9, 16-18.	9.4	36
71	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2â€“Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	1.1	34
72	Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters. PLoS ONE, 2012, 7, e31087.	2.5	33

#	Article	IF	Citations
73	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	33
74	Axl Receptor Axis: A New Therapeutic Target in LungÂCancer. Journal of Thoracic Oncology, 2016, 11, 1357-1362.	1.1	32
75	AXL Inhibition Induces DNA Damage and Replication Stress in Nonâ€“Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research, 2021, 19, 485-497.	3.4	32
76	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget, 2016, 7, 565-579.	1.8	31
77	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. Journal of Clinical Oncology, 2021, 39, 3633-3644.	1.6	27
78	The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. British Journal of Cancer, 2021, 124, 857-859.	6.4	26
79	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS ONE, 2020, 15, e0234505.	2.5	25
80	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	12.8	24
81	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. OncoImmunology, 2016, 5, e1234570.	4.6	23
82	drexplorer: A tool to explore doseâ€“response relationships and drugâ€“drug interactions. Bioinformatics, 2015, 31, 1692-1694.	4.1	22
83	A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. British Journal of Cancer, 2021, 125, 1333-1340.	6.4	22
84	<scp>eIF</scp>2Î², a subunit of translationâ€initiation factor <scp>EIF</scp>2, is a potential therapeutic target for nonâ€small cell lung cancer. Cancer Science, 2018, 109, 1843-1852.	3.9	20
85	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer & Metabolism, 2021, 9, 33.	5.0	20
86	Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2019, 37, TPS8576-TPS8576.	1.6	19
87	Identification of proteasomal catalytic subunit <scp>PSMA</scp>6 as a therapeutic target for lung cancer. Cancer Science, 2017, 108, 732-743.	3.9	18
88	SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 4095-4105.	2.8	17
89	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Research, 2021, 81, 1398-1412.	0.9	16
90	Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e203277.	5.9	15

#	Article	IF	Citations
91	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 531-540.	2.6	15
92	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clinical Cancer Research, 2019, 25, 346-357.	7.0	14
93	Teaching an Old Dog New Tricks: Drug Repositioning in Small Cell Lung Cancer. Cancer Discovery, 2013, 3, 1333-1335.	9.4	13
94	A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow. Cancer Discovery, 2014, 4, 991-994.	9.4	13
95	A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget, 2017, 8, 81441-81454.	1.8	12
96	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget, 2018, 9, 14268-14284.	1.8	12
97	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances, 2017, 3, e1600957.	10.3	10
98	HIRA deficiency in muscle fibers causes hypertrophy and susceptibility to oxidative stress. Journal of Cell Science, 2017, 130, 2551-2563.	2.0	9
99	Poly ADPâ€ribose polymeraseâ€1 as a potential therapeutic target in Merkel cell carcinoma. Head and Neck, 2018, 40, 1676-1684.	2.0	9
100	Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. Frontiers in Oncology, 2021, 11, 757323.	2.8	9
101	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. British Journal of Cancer, 2022, 127, 569-576.	6.4	8
102	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	6.4	7
103	PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?. Journal of Thoracic Oncology, 2019, 14, 1323-1326.	1.1	7
104	Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?. Cancer Discovery, 2019, 9, 1340-1342.	9.4	7
105	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	3.7	7
106	New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e276-e285.	3.8	7
107	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. Journal of Experimental and Clinical Cancer Research, 2022, 41, 109.	8.6	7
108	Durable, exceptional response to temozolomide in a patient with extensive-stage small cell lung cancer (ES-SCLC) metastatic to brain. Cancer Treatment and Research Communications, 2017, 10, 17-20.	1.7	5

#	Article	IF	Citations
109	A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. Cancers, 2021, 13, 2022.	3.7	5
110	Abstract 384: Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer. Cancer Research, 2021, 81, 384-384.	0.9	4
111	Germline and Somatic Smoothened Mutations in Nonâ€“Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precision Oncology, 2017, 1, 1-10.	3.0	3
112	Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era. Cancer, 2019, 125, 496-498.	4.1	3
113	This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell, 2020, 37, 5-7.	16.8	3
114	Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer. , 2019, , .		3
115	Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse. , 2018, , .		3
116	Selecting Reliable mRNA Expression Measurements across Platforms Improves Downstream Analysis. Cancer Informatics, 2016, 15, CIN.S38590.	1.9	2
117	ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer. EBioMedicine, 2019, 39, 5-6.	6.1	2
118	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	8.6	2
119	Reply to F. Liang. Journal of Clinical Oncology, 2019, 37, 259-259.	1.6	1
120	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leukemia Research, 2020, 98, 106445.	0.8	1
121	Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer. , 2019, , .		1
122	Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers. Cancers, 2019, 11, 239.	3.7	0
123	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
124	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
125	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
126	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0